Incidence of anti-topoisomerase I antibody seroconversion and clinical association in systemic sclerosis
Article Sidebar
Main Article Content
Abstract
Anti-topoisomerase I antibody (ATA) is an autoantibody associating with a poor prognosis in systemic sclerosis (SSc). The changing of ATA from negative to positive or vice versa might have an effect on the outcome. We aimed to define the incidence and to determine the association between clinical parameters and ATA seroconversion. A historical cohort study of adult SSc patients who attended the Scleroderma Clinic, Khon Kaen University, Thailand was conducted. We included all patients tested at least twice for ATA during January 2008-May 2018. ATA positive seroconversion was set when ATA was initially negative but switched to positive over the period of follow-up while ATA negative seroconversion was fulfilled when ATA changed from positive to negative. Forty-eight SSc patients were tested for ATA at least twice. ATA positive seroconversion was not detected during follow up while 2 cases (4.2%) were defined as ATA negative seroconversion with the incidence of 1.0 per 100 person-years (95%CI 0.02-0.4). Both patients presented regression of skin thickness and pulmonary arterial hypertension (PAH). There was no parameter associated with ATA negative seroconversion. There was a low incidence of both ATA negative and positive seroconversion among SSc patients and no significant clinical association by repeating test was detected. Repeating test for ATA may have low clinical utility for SSc patients.
Article Details
References
Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev. 2003;2(4):181-191.
Silver RM. Clinical aspects of systemic sclerosis (scleroderma). Ann Rheum Dis. 1991;50(Suppl 4):854-861.
Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res. 2003;49(3):399-412.
Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997;103(3):242-248.
Foocharoen C, Watcharenwong P, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais. Int J Rheum Dis 2017;20(10):1572-1581.
Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.
Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol. 2012;22(2):272-279.
Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin. Rheumatol. 2013;32(5):617-621.
Poormoghim H, Moghadam AS, Lakeh MM, Jafarzadeh M, Asadifar B, Ghelman M, et al. Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int. 2013;33(8):1943-1950.
Jacobsen S, Halberg P, Ullman S, Venrooij WJ, Madsen MH, Wiik A, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol. 1998;37(1):39-45.
Villalta D, Imbastaro T, Giovanni SD, Lauriti C, Gabini M, Turi MC, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012;12(2):1141-120.
Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15(1):102-109.
Foocharoen C, Suwannachat P, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R, et al. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I. Int J Rheum Dis. 2016;19(3):312-320.
Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 2000;43(5):1074-1084.
Hasegawa M, Hatta Y, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Mod Rheumatol. 2013;23(5):913-919.
Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581-590.
Hoogen FV, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988;15:202-205.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1): 1801913.
Savarino E, Furnari M, de Bortoli N, Martinucci I, Bodini G, Ghio M, et al. Gastrointestinal involvement in systemic sclerosis. Presse Med. 2014;43:e279-291.
Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012;43(3):249-255.
Hildebrandt S, Jäckh G, Weber S, Peter HH. A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int. 1993;12(6):231-234.
Basu D, Reveille JD. Anti-scl-70. Autoimmunity. 2005;38(1):65-72.
Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford). 2004;43(5):596-602.
Mayes MD, Lacey JV, Dimmer JB, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246-2255.
Alvarado PC, Pardo AL, Rodriguez NC, Villarraga AR, Anaya JM. Systemic sclerosis: a world wide global analysis. Clin Rheumatol. 2009;28(7):757-765.
Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, Montagna GL, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139-153.
Park SK, Kim TH, Jun JB, Jung SS, Bae SC, Kim TY, et al. The clinical features and autoantibody profile in progressive systemic sclerosis of Korea. J Korean Rheumatol Assoc. 2001;8(4):243-252.
Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37(1):75-83.
Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516-522.